Q3 Earnings Forecast for Quanterix Issued By Leerink Partnrs

Quanterix Co. (NASDAQ:QTRX) – Equities researchers at Leerink Partnrs increased their Q3 2024 EPS estimates for Quanterix in a research report issued on Tuesday, November 12th. Leerink Partnrs analyst P. Souda now forecasts that the company will earn ($0.19) per share for the quarter, up from their previous forecast of ($0.20). The consensus estimate for Quanterix’s current full-year earnings is ($0.88) per share. Leerink Partnrs also issued estimates for Quanterix’s Q4 2024 earnings at ($0.20) EPS, Q3 2025 earnings at ($0.20) EPS and Q4 2025 earnings at ($0.21) EPS.

Other equities research analysts also recently issued research reports about the stock. Scotiabank reduced their price target on shares of Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research report on Monday, August 12th. TD Cowen upped their price objective on shares of Quanterix from $13.50 to $16.00 and gave the company a “hold” rating in a research note on Wednesday.

Quanterix Stock Performance

Shares of NASDAQ:QTRX opened at $11.92 on Friday. Quanterix has a 52 week low of $10.50 and a 52 week high of $29.70. The firm has a 50 day simple moving average of $12.97 and a 200 day simple moving average of $14.01.

Insider Buying and Selling

In other Quanterix news, Director David R. Walt acquired 47,000 shares of Quanterix stock in a transaction dated Tuesday, August 20th. The stock was bought at an average cost of $13.29 per share, with a total value of $624,630.00. Following the acquisition, the director now owns 1,487,342 shares of the company’s stock, valued at approximately $19,766,775.18. The trade was a 3.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Quanterix

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in shares of Quanterix by 112.6% during the 3rd quarter. FMR LLC now owns 30,242 shares of the company’s stock worth $392,000 after buying an additional 16,020 shares during the period. Algert Global LLC grew its position in shares of Quanterix by 75.9% during the 3rd quarter. Algert Global LLC now owns 137,833 shares of the company’s stock worth $1,786,000 after buying an additional 59,496 shares during the period. Intech Investment Management LLC acquired a new stake in shares of Quanterix during the 3rd quarter worth approximately $170,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Quanterix during the 3rd quarter worth approximately $500,000. Finally, GSA Capital Partners LLP acquired a new stake in shares of Quanterix during the 3rd quarter worth approximately $258,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.